Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6195871 | 0.98 | KCNH2 (0.55) | KCNH2HRH3CA12CA1CA2 | |
| SCHEMBL29554790 | 0.89 | RAB9A (0.63) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL27888979 | 0.85 | KCNH2 (0.73) | KCNH2HRH3CA12CA1CA2 | |
| SCHEMBL1531725 | 0.85 | KCNH2 (0.59) | KCNH2HRH3CA12CA1CA2 | |
| SCHEMBL7222401 | 0.84 | CA12 (0.49) | KCNH2HRH3CA12CA1CA2 | |
| Hydrogen Sulfide SCHEMBL27863722 | 0.83 | KCNH2 (0.58) | KCNH2HRH3CA12CA1CA2 | |
| SCHEMBL29072978 | 0.82 | PARP10 (0.59) | NPC1RAB9ASMN1; SMN2ALDH1A1HSD11B1 | |
| SCHEMBL31734550 | 0.82 | RAB9A (0.52) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL11123314 | 0.81 | KCNH2 (0.56) | KCNH2HRH3CA12CA1CA2 | |
| SCHEMBL1193744 | 0.81 | KCNH2 (0.56) | KCNH2HRH3CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | claimed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| US-20020151501-A1 | Compounds having growth hormone releasing activity | BOWERS CYRIL Y (US) | 2002-10-17 | — | — | US | claimed |
| EP-1159292-A2 | COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | Administrators of The Tulane Educational Fund (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2000009537-A2 | COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2000-02-24 | — | — | WO | claimed |
| EP-3596061-B1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | ARGONAUT THERAPEUTICS LTD (GB) | 2023-09-06 | — | — | EP | disclosed |
| CN-111787916-B | Dihydroceramide desaturase inhibitors for treating diseases | 森陶鲁斯治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-111787916-A | Inhibitors of dihydroceramide desaturase for the treatment of diseases | 森陶鲁斯治疗公司 | 2020-10-16 | — | — | CN | disclosed |
| EP-2760862-B1 | 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2015-10-21 | — | — | EP | disclosed |
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | disclosed |
| EP-2760862-A1 | 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI (FR) | 2014-08-06 | — | — | EP | disclosed |
| WO-2004046107-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | WO | disclosed |
| CN-1137886-C | 2,3-dioxo-1,2,3,4-tetrahydro-quinoyxalinyl derivatives | ��˹��ŵ�� | 2004-02-11 | — | — | CN | disclosed |
| US-6468974-B1 | OLIGOPEPTIDES THAT PROVIDE DESIRABLE IN VITRO AND IN VIVO GROWTH HORMONE RELEASING ACTIVITY AND HAVE AT LEAST ONE OTHER DESIRABLE BIOLOGICAL ACTIVITY SUCH AS INCREASED RETENTION TIME | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2002-10-22 | — | — | US | disclosed |
| US-20020151501-A1 | Compounds having growth hormone releasing activity | BOWERS CYRIL Y (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1159292-A2 | COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | Administrators of The Tulane Educational Fund (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000009537-A2 | COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2000-02-24 | — | — | WO | disclosed |
| US-4054604-A | MICROBIOCIDES, HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1977-10-18 | — | — | US | disclosed |
| US-3981868-A | MICROBIOCIDES, HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151501-A1 | Compounds having growth hormone releasing activity | GHSR, GHRHR, NPY1R | KCNH2 4286/4885HRH3 597/4885CA12 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.